Cherqaoui Driss - Profil du chercheur

Informations du chercheur

Nom complet

Cherqaoui Driss

Grade

PES

Spécialité

Chimie organique

Thématique de recherche

Synthèse organique et modélisation moléculaire

Laboratoire

Laboratoire de Chimie Moléculaire

Établissement

Faculté des Sciences Semlalia Marrakech

Ouvrages (0 au total)

Aucun ouvrage disponible.

Projets (1 au total)

Modélisation moléculaire : Contribution à la conception d’inhibiteurs du VIH

Type: Non spécifié

Début: 01/01/2017

Fin: 30/12/2018

Organisme financeur:

Agence Universitaire de la Francophonie” and the Scientific Research Fund of Bulgaria. under project DNTS/FrPh01/1.

Publications (29 au total)

In silico design and analysis of NS4B inhibitors against hepatitis C virus

Auteur: Ismail Hdoufane, Imane Bjij, Mehdi Oubahmane, Mahmoud E.S Soliman, Didier Villemin, Driss Cherqaoui

Revue: Journal of Biomolecular Structure and Dynamics

Année: 2022

DOI: 10.1080/07391102.2020.1839561

Monte Carlo Method and GA-MLR-Based QSAR Modeling of NS5A Inhibitors against the Hepatitis C Virus

Auteur: Wissal Liman, Mehdi Oubahmane, Ismail Hdoufane, Imane Bjij, Didier Villemin, Rachid Daoud, Driss Cherqaoui, Achraf El Allali

Revue: Molecules

Année: 2022

DOI: 10.3390/molecules27092729

Host Cell Proteases Mediating SARS-CoV-2 Entry: An Overview

Auteur: Driss Cherqaoui, Mehdi Oubahmane, Ismail Hdoufane, Imane Bjij, Nouhaila Ait Lahcen, Didier Villemin, Rachid Daoud, Achraf El Allali

Revue: Current Topics in Medicinal Chemistry

Année: 2022

DOI: 10.2174/1568026622666220726122339

Hybrid Molecules as Potential Drugs for the Treatment of HIV: Design and Applications

Auteur: Wissal Liman, Nouhaila Ait Lahcen, Mehdi Oubahmane, Ismail Hdoufane, Driss Cherqaoui, Rachid Daoud, Achraf El Allali

Revue: Pharmaceuticals

Année: 2022

DOI: 1092 10.3390/ph15091092

Development of QSAR Models Using Singular Value Decomposition Method: A Case Study for Predicting Anti-HIV-1 and Anti-HCV Biological Activities

Auteur: Ismail Hdoufane, Daoud Ounaissi, Azzouz Dermoune, Driss Cherqaoui

Revue: Biointerface Research in Applied Chemistry

Année: 2022

DOI: 10.33263/BRIAC123.30903105

Targeting Protein Degradation in Cancer Treatment

Auteur: Imane Bjij, Ismail Hdoufane, Mahmoud Soliman, Menče Najdoska-Bogdanov, Driss Cherqaoui

Revue: Current Chemical Biology

Année: 2021

DOI: 10.2174/2212796814999200609131623

COVID-19: In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2

Auteur: Mehdi Oubahmane, Ismail Hdoufane, Imane Bjij, Carola Jerves, Didier Villemin, Driss Cherqaoui

Revue: Journal of Molecular Structure

Année: 2021

DOI: 10.1016/j.molstruc.2021.130897

Di-μ-oxidovanadium(V) di-nuclear complexes: Synthesis, X-ray, DFT modeling, Hirshfeld surface analysis and antioxidant activity

Auteur: Ali Hasnaoui, Ismail Hdoufane, Abderrahim Alahyane, Abdallah Nayad, Driss Cherqaoui, Mustapha Ait Ali, Larbi El Firdoussi

Revue: Inorganica Chimica Acta

Année: 2020

DOI: 10.1016/j.ica.2019.119276

Synthesis of diverse isoxazolylamino-2-(aryl)acetamides using one-pot Multicomponent Reactions: X-ray, Hirshfeld analysis and DFT modeling

Auteur: Mohammed Loubidi, Jabrane Jouha, Ismail Hdoufane, Mohamed El Hafi, Zahira Tber, Driss Cherqaoui, Joel T. Mague

Revue: Journal of Molecular Structure

Année: 2020

DOI: 10.1016/j.molstruc.2019.127178

« Précédent 1 2 3 4 Suivant »

Communications (22 au total)

In silico identification of novel NS5A inhibitors with potential anti-HCV activity

Manifestation: UM6P Doctoral Day 2023

Date: 2023-09-25

Organisation: Université Mohammed VI Polytechnique, Ben Guérir, Morocco

QSAR modeling, ADMET predictions and molecular docking analysis of a series of Dimeric phenylthiazole derivatives as NS5A inhibitors

Manifestation: 33th edition of the International Congress of “Apollonia” University of Iasi

Date: 2023-03-03

Organisation: Apollonia University of Iasi, Iasi, Roumanie

Identification of novel TMPRSS4 inhibitors via homology modeling, molecular docking and molecular dynamics

Manifestation: 33rd edition of the International Congress of “Apollonia” University of Iasi

Date: 2023-03-02

Organisation: Apollonia University of Iasi, Iasi, Roumanie

8. In silico studies toward the identification of potential glycoprotein inhibitors as anti-Ebola agents

Manifestation: 33rd edition of the International Congress of “Apollonia” University of Iasi

Date: 2023-03-02

Organisation: Apollonia University of Iasi, Iasi, Roumanie

Identification of new potential HCV inhibitors

Manifestation: International bioinformatics conference (IBC 2022):Drug Design

Date: 2022-10-08

Organisation: Tanger, Maroc

In Silico approaches for the design of HCV inhibitors

Manifestation: Science week talks

Date: 2022-05-31

Organisation: Université Mohammed VI Polytechnique, Ben Guérir, Morocco

In silico QSAR-based discovery and molecular docking of novel inhibitors of the SARS-COV-2 main protease (Mpro)

Manifestation: 32nd edition of the international congress of Apollonia University "Preparing the Future by Promoting Excellence"

Date: 2022-03-02

Organisation: Iasi, Romania

QSAR Study of NS5A Inhibitors against Hepatitis C Virus using the Monte Carlo Optimization and the Genetic Algorithm Multiple Linear Regression(GA-MLR) Models

Manifestation: 6th International Conference on Computational Science and Technology 2021-ICCST

Date: 2021-10-31

Organisation: Faculty of Pharmacy, Chiang Mai University, Thailand

In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2

Manifestation: 6th International Conference on Computation For Sciences and Technology

Date: 2021-10-30

Organisation: Thailand

1 2 3 Suivant »

Thèses (3 au total)

In Silico Drug Design of Potent SARS-CoV-2 Inhibitors

Auteur: Mehdi OUBAHMANE

Directeur: Cherqaoui Driss

Soutenance: 2023

Molecular Modeling: QSAR Studies on Reverse Transcriptase and Gp120 HIV-1 and NS4B HCV Inhibitors

Auteur: HDOUFANE Ismail

Directeur: Cherqaoui Driss

Soutenance: 2021

Targeting Protein Degradation as a Potential and Emerging Therapeutic Approach in Cancer Drug Discovery: Combinatorial In Silico Modeling to Explore the Covalent & Non-covalent Inhibition of Nedd4-1 E3 Ubiquitin Ligase

Auteur: BJIJ Imane

Directeur: Cherqaoui Driss

Soutenance: 2019

Informations du chercheur

Nom complet

Grade

Spécialité

Thématique de recherche

Laboratoire

Établissement

Ouvrages (0 au total)

Projets (1 au total)

Mod&eacute;lisation mol&eacute;culaire : Contribution &agrave; la conception d&rsquo;inhibiteurs du VIH

Publications (29 au total)

In silico design and analysis of NS4B inhibitors against hepatitis C virus

Monte Carlo Method and GA-MLR-Based QSAR Modeling of NS5A Inhibitors against the Hepatitis C Virus

Host Cell Proteases Mediating SARS-CoV-2 Entry: An Overview

Hybrid Molecules as Potential Drugs for the Treatment of HIV: Design and Applications

Development of QSAR Models Using Singular Value Decomposition Method: A Case Study for Predicting Anti-HIV-1 and Anti-HCV Biological Activities

Targeting Protein Degradation in Cancer Treatment

COVID-19: In silico identification of potent &alpha;-ketoamide inhibitors targeting the main protease of the SARS-CoV-2

Di-&mu;-oxidovanadium(V) di-nuclear complexes: Synthesis, X-ray, DFT modeling, Hirshfeld surface analysis and antioxidant activity

Synthesis of diverse isoxazolylamino-2-(aryl)acetamides using one-pot Multicomponent Reactions: X-ray, Hirshfeld analysis and DFT modeling

Communications (22 au total)

In silico identification of novel NS5A inhibitors with potential anti-HCV activity

QSAR modeling, ADMET predictions and molecular docking analysis of a series of Dimeric phenylthiazole derivatives as NS5A inhibitors

Identification of novel TMPRSS4 inhibitors via homology modeling, molecular docking and molecular dynamics

8. In silico studies toward the identification of potential glycoprotein inhibitors as anti-Ebola agents

Identification of new potential HCV inhibitors

In Silico approaches for the design of HCV inhibitors

In silico QSAR-based discovery and molecular docking of novel inhibitors of the SARS-COV-2 main protease (Mpro)

QSAR Study of NS5A Inhibitors against Hepatitis C Virus using the Monte Carlo Optimization and the Genetic Algorithm Multiple Linear Regression(GA-MLR) Models

In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2

Thèses (3 au total)

In Silico Drug Design of Potent SARS-CoV-2 Inhibitors

Molecular Modeling: QSAR Studies on Reverse Transcriptase and Gp120 HIV-1 and NS4B HCV Inhibitors

Targeting Protein Degradation as a Potential and Emerging Therapeutic Approach in Cancer Drug Discovery: Combinatorial In Silico Modeling to Explore the Covalent &amp; Non-covalent Inhibition of Nedd4-1 E3 Ubiquitin Ligase

Modélisation moléculaire : Contribution à la conception d’inhibiteurs du VIH

COVID-19: In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2

Di-μ-oxidovanadium(V) di-nuclear complexes: Synthesis, X-ray, DFT modeling, Hirshfeld surface analysis and antioxidant activity

Targeting Protein Degradation as a Potential and Emerging Therapeutic Approach in Cancer Drug Discovery: Combinatorial In Silico Modeling to Explore the Covalent & Non-covalent Inhibition of Nedd4-1 E3 Ubiquitin Ligase